Niagen Bioscience Reports 37% Revenue Growth to $31.1 Million in Latest Quarter

Niagen Bioscience, Inc. reported significant financial growth in its latest quarterly filing, with net sales reaching $31.1 million for the three months ended June 30, 2025, a 37% increase from $22.7 million in the same period last year. For the first half of 2025, the company generated $61.6 million in net sales, up from $44.9 million in the prior year, marking a 37% increase. The company also achieved a net income of $3.6 million for the second quarter, compared to a loss of $15,000 in the same quarter of 2024. For the six months ended June 30, 2025, net income totaled $8.7 million, a significant turnaround from a loss of $507,000 in the previous year.

The company's financial performance reflects substantial growth in both its Consumer Products and Ingredients segments. Sales from the Consumer Products segment, primarily driven by the Tru Niagen® brand, increased by 22% to $22.7 million for the second quarter, while the Ingredients segment saw a remarkable 131% increase in sales to $7.6 million. The growth in the Ingredients segment was bolstered by higher sales of food-grade and pharmaceutical-grade Niagen®, which began contributing to revenue in the second half of 2024. The company noted that e-commerce sales were particularly strong, contributing significantly to the overall sales increase.

Operationally, Niagen Bioscience has made strategic moves to enhance its market position. The company executed a Supply Agreement with W. R. Grace & Co. for the exclusive supply of Nicotinamide-beta-Riboside Chloride, which is expected to secure a steady inventory supply through April 2029. Additionally, the company amended its lease in Longmont, Colorado, extending it through October 2030, which reflects its commitment to maintaining operational stability. As of June 30, 2025, Niagen Bioscience reported total assets of $91.5 million, up from $68.3 million at the end of 2024, driven by increased cash reserves and inventory levels.

The company also reported a notable increase in its employee headcount, which is indicative of its expanding operations. As of June 30, 2025, Niagen Bioscience had approximately 79,586 shares of common stock outstanding, reflecting a growth in equity as the company continues to attract investment. The company’s cash and cash equivalents stood at $60.5 million, providing a solid liquidity position to support ongoing operations and potential future investments.

Looking ahead, Niagen Bioscience anticipates continued growth driven by its expanding product lines and market presence. The company expects that its current cash reserves and projected sales will be sufficient to meet its financial obligations over the next twelve months. However, it may seek additional capital to support long-term strategic objectives. The management remains optimistic about the future, citing strong customer acquisition and retention efforts, particularly in the e-commerce space, as key drivers of growth.